As high CD103+CD8+ TIL levels are linked with improved CRC patient survival [39], our analyses suggest that colonic and intratumoral CD103+CD8+ T cells with prominent PD-1 expression would be frequently targeted by anti-PD-1 ICI. Here, CD8A is linked to colorectal carcinoma.